Identification of a novel dual-targeting peptide inhibitor of SARS-CoV-2 RBD and NRP1 through structure-based virtual screening
In conclusion, peptide-1 is a highly effective and low-toxicity antiviral inhibitor that dual-targets RBD and NRP1.
Authors
- Lixia Guan
- Mei Yu (ORCID: https://orcid.org/0000-0001-7952-6344)
- Miaomiao Niu (ORCID: https://orcid.org/0000-0001-6368-8525)
- Gang Wang (ORCID: https://orcid.org/0000-0002-0833-4887)
- Yuting Wang (ORCID: https://orcid.org/0000-0002-1443-2643)
- Li Feng (ORCID: https://orcid.org/0000-0003-0850-0061)
- Nan Yao (ORCID: https://orcid.org/0000-0001-9161-1058)
- Shengnan Yin
Institutions
- Nanjing University of Chinese Medicine (CN)
- China Pharmaceutical University (CN)
- Nantong University (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- Taizhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3389/fphar.2025.1691679
- Primary Topic
- Pharmacological Receptor Mechanisms and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nanjing University of Chinese Medicine
- Nanjing University